

Novoeight® — Designed to fit into their lives

A recombinant factor VIII for today's
generation of people living with
hemophilia A¹

Michael, 30 years old, lives with hemophilia A.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Please see additional Important Safety Information throughout and on page 22.
Please see [Prescribing Information](#).



novoeight®
Antihemophilic Factor
(Recombinant)